Sanofi commits €400M to another cancer R&D pact, this time with Innate Pharma

John Carroll

Less than a year after downsized its drug R&D operations, the giant has struck back-to-back deals to launch new immuno-oncology drug programs, looking to continue to beef up in a field where the company has fallen far behind its top rivals.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS